Sayed MehdiHussainHamadaniMD

Abstracts/Posters

• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Imm...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0406
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Tr...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018